– Analysis partnership strengthens Bahrain’s healthcare innovation ecosystem and highlights GCC pre-clinical analysis excellence by pioneering biomaterial know-how for power wound therapeutic
Manama, Nov. 27 (BNA): The Royal Faculty of Surgeons in Eire (RCSI) in Dublin, RCSI Medical College of Bahrain, and the Royal Medical Providers have introduced the profitable development of a joint analysis venture geared toward enhancing wound therapeutic by the event of an revolutionary biomaterial and a brand new medical gadget.
This analysis partnership was carried out underneath the management of Brigadier (Dr) Fahad bin Khalifa Al Khalifa, Commander of the Royal Medical Providers; Professor Stephen Atkin, Head of the Faculty of Postgraduate Research and Analysis at RCSI Medical College of Bahrain; and Professor Fergal O’Brien, Deputy Vice Chancellor for Analysis & Innovation and Head of the Tissue Engineering Analysis Group at RCSI in Dublin. The collaboration has achieved promising pre-clinical ends in growing a novel biomaterial that accelerates wound therapeutic.
The venture introduced collectively medical and scientific experience from Bahrain and Eire, led by Professor Michael Keogh, Affiliate Professor in Human Biology and Head of the Tissue Engineering Analysis Group at RCSI Medical College of Bahrain, and Dr. Mohammed Al Muharraqi, Director of the RCSI–RMS Analysis Collaboration and Director of the Crown Prince Centre for Coaching & Medical Analysis. They had been supported by Dr. Martin Maresch, Vascular and Endovascular Surgeon on the Royal Medical Providers, and a crew of 11 analysis and medical specialists. The crew efficiently developed and demonstrated a biomaterial that enhances tissue restore by enhancing blood vessel formation and decreasing scarring, leading to higher therapeutic in contrast with conventional medical dressings. Pre-clinical outcomes confirmed that the biomaterial integrates successfully with surrounding tissue and promotes extra full therapeutic in aged and diabetic sufferers.
The latest section of the crew’s work supported the DocLeaf venture, which focuses on growing a medical gadget for treating power wounds and acquired €1 million in analysis funding from Enterprise Eire. The gadget goals to deal with localised tissue hypoxia and stimulate the physique’s pure restore mechanisms, reaching quicker and extra sustainable therapeutic. Over the previous 18 months, the venture has progressed from an preliminary idea developed at RCSI in Dublin to the primary in vivo examine on the RMS Crown Prince Centre for Coaching & Medical Analysis in Bahrain.
Dr. Mohammed Al Muharraqi stated: “The progress achieved within the DocLeaf venture stands as a testomony to our experience in superior biomedical analysis and highlights the rising position of the Kingdom of Bahrain in pioneering medical analysis that addresses international well being challenges.”
Professor Sameer Otoom, President of RCSI Medical College of Bahrain, added: “This initiative demonstrates the power of our worldwide analysis collaborations and our dedication to enhancing well being outcomes by scientific discovery. We purpose to translate these outcomes into sensible options that immediately improve affected person care.”
Professor Fergal O’Brien stated: “I’m very grateful to the crew in Bahrain for his or her dedication to advancing the DocLeaf venture. Enterprise Eire have expressed their appreciation for the standard and impression of our joint analysis, and I’m assured in our collective potential to steer superior analysis initiatives between Eire and Bahrain.”
Persistent wounds are an rising international concern, with diabetic sufferers significantly prone to non-healing ulcers and associated infections. This partnership represents a strategic step inside Bahrain’s healthcare innovation ecosystem, strengthening its place as a regional hub for utilized and pre-clinical analysis.
The joint analysis goals to enhance therapeutic of diabetic wounds, venous leg ulcers, and power wounds, and assist pores and skin regeneration by accelerating tissue restore and reaching higher therapeutic outcomes. These advances have the potential to boost affected person restoration, forestall an infection, protect limbs, and enhance high quality of life for sufferers with diabetic foot ulcers and different power wounds.
The crew anticipates that this analysis will result in the institution of a brand new start-up in 2026, paving the way in which for commercialising the know-how and integrating it into medical purposes.
A.S
